This article or section may have been copied and pasted from a source, possibly in violation of Wikipedia's copyright policy. Please remedy this by editing this article to remove any non-free copyrighted content and attributing free content correctly, or flagging the content for deletion. Please be sure that the supposed source of the copyright violation is not itself a Wikipedia mirror.(December 2016)
This article needs attention from an expert in Medicine. Please add a reason or a talk parameter to this template to explain the issue with the article. WikiProject Medicine may be able to help recruit an expert.(March 2013)
It has been discovered that when GHRP-6 and insulin are administered simultaneously, GH response to GHRP-6 is increased (1). However, the consumption of carbohydrates and/or dietary fats, around the administration window of GH secretagogues significantly blunts the GH release. A recent study in normal mice showed significant differences in body composition, muscle growth, glucose metabolism, memory and cardiac function in the mice being administered the GHRP-6 (2). There are still many questions regarding this fairly new compound, scientists are hoping to gain a better clinical understanding of the peptide through further research over the next few years.
GH secretagogues differ from exogenous rHGH in their effects primarily because endogenous GH contains all five isoforms of growth hormone, whereas exogenous GH contains only the 20 kilodalton isoform. Different isoforms affect tissues in discreet ways that the 20 kDa isoform cannot. Administration of GH secretagogues causes a pulse-release of GH from the pituitary which is cleared from the body within a few hours. This does not significantly raise plasma insulin-like growth factor 1 (IGF-1) levels.
Peñalva, A; Carballo, A; Pombo, M; Casanueva, FF; Dieguez, C (1993). "Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man". The Journal of Clinical Endocrinology and Metabolism. 76 (1): 168–71. PMID8421084. doi:10.1210/jc.76.1.168.
Camanni, F; Ghigo, E; Arvat, E (1998). "Growth hormone-releasing peptides and their analogs". Frontiers in neuroendocrinology. 19 (1): 47–72. PMID9465289. doi:10.1006/frne.1997.0158.
McGirr, R; McFarland, MS; McTavish, J; Luyt, LG; Dhanvantari, S (2011). "Design and characterization of a fluorescent ghrelin analog for imaging the growth hormone secretagogue receptor 1a". Regulatory peptides. 172 (1-3): 69–76. PMID21893106. doi:10.1016/j.regpep.2011.08.011.